Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Fibrosis and structural remodeling of the lung tissue can significantly impair lung function,
often with fatal consequences. The etiology of pulmonary fibrosis (PF) is diverse and …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

This document is an international evidence-based guideline on the diagnosis and
management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Pulmonary fibrosis is a chronic lung disease characterized by excessive accumulation of
extracellular matrix (ECM) and remodeling of the lung architecture. Idiopathic pulmonary …

Some of the most pressing challenges associated with interstitial lung disease (ILD) are how
best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD) …

Pulmonary fibrosis and architectural remodeling of tissues can severely disrupt lung
function, often with fatal consequences. The etiology of pulmonary fibrotic diseases is varied …

Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …

Fibrosis is the formation of fibrous connective tissue in response to injury. It is characterized
by the accumulation of extracellular matrix components, particularly collagen, at the site of …